CPC A61K 38/2086 (2013.01) [A61K 38/20 (2013.01); A61P 1/00 (2018.01); A61P 17/00 (2018.01); A61P 19/02 (2018.01); A61P 29/00 (2018.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); A61P 37/02 (2018.01); A61P 37/04 (2018.01); C07K 14/5443 (2013.01); C07K 14/7155 (2013.01); C07K 19/00 (2013.01); C12N 15/62 (2013.01); A61K 47/642 (2017.08); A61K 2300/00 (2013.01); C07K 16/30 (2013.01); C07K 2319/30 (2013.01)] | 15 Claims |
1. One or more nucleic acids encoding an IL-15 protein complex comprising a soluble fusion protein (I) and a soluble fusion protein (II), wherein:
the soluble fusion protein (I) comprises an IL-15 polypeptide; and the soluble fusion protein (II) comprises an IL-15Rα polypeptide;
wherein the soluble fusion protein (I) comprises an amino acid Cys substitution at a position corresponding to residue Q48, V49, L52 or E53 of the IL-15 polypeptide having the amino acid sequence of SEQ ID NO: 1, and the soluble fusion protein (II) comprises an amino acid Cys substitution at a position corresponding to residue A37, G38, S40 or L42 of the IL-15Rα polypeptide having the amino acid sequence of SEQ ID NO: 4, and a disulfide bond is formed by Cys residues of the soluble fusion protein (II) and the soluble fusion protein (I).
|